4D pharma plc (LON: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announced the presentation of a poster detailing its Phase I/II clinical study of MRx0518 combined with KEYTRUDA® in patients with solid tumours who have failed prior anti-PD-1 therapy at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA. ASCO is the world’s largest conference in the field of clinical oncology and attracts approximately 39,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
Alex Stevenson, 4D’s Chief Scientific Officer, commented: “We are pleased to have presented this poster at such a prestigious oncology meeting”.
The poster describes the proposed mechanism of action of MRx0518 and preclinical data in addition to details about the Phase I/II study which is currently enrolling patients. This clinical study is taking place at The University of Texas MD Anderson Cancer Center and is part of 4D’s clinical collaboration with Merck & Co., Inc., (known as MSD outside the United States and Canada). The poster was presented on Saturday 1 June during the session, “Developmental Immunotherapy and Tumor Immunobiology” (poster number TPS2670). The lead author of the poster was Shubham Pant, M.D., MD Anderson Cancer Center, Texas.
A copy of the poster can be viewed at https://www.4dpharmaplc.com/en/newsroom/posters-and-publications
